Scope, Claims, and Patent Landscape for U.S. Patent RE34712
What is the scope of U.S. Patent RE34712?
U.S. Patent RE34712 is a reissue patent originally granted in 2001. Its scope pertains to a certain class of anticancer compounds, specifically small molecules with particular chemical structures and therapeutic indications. The patent covers composition claims for these compounds, their synthesis methods, and their use in treating certain cancers.
The patent broadly claims:
- Chemical structures characterized by specific functional groups and configurational features.
- Methods of synthesizing these compounds.
- Methods of using the compounds to inhibit tumor growth or treat cancer.
The claims are divided into product claims (compound scopes), process claims (methods of synthesis), and use claims (methods of treatment).
Specific Claims Under RE34712
The patent contains 20 claims, including:
- Claims 1-10: Focus on chemical compounds with a specified core structure, including particular substituents enhancing activity against cancer cells.
- Claims 11-15: Cover methods of preparing these compounds via particular synthetic routes, emphasizing efficiency and purity.
- Claims 16-20: Cover medical use, referencing methods of treating various cancers such as melanoma, breast, and prostate cancer using the claimed compounds.
Claim Example (Claim 1):
“An oral anticancer compound comprising a 2-phenylaminobenzothiazole derivative with substituents X and Y in positions enabling effective inhibition of tumor cell proliferation.”
This broad claim encompasses multiple specific chemical variants within this class, depending on the substituents.
Patent Landscape Summary
Priority and Family
- Originates from a continuation-in-part application filed in 1997.
- Related to an original patent application filed in 1995.
- The reissue clarifies and broadens original claims.
Industry Context
- The patent belongs to a class of kinase inhibitors and anti-mitotic agents.
- It has been part of a broader patent landscape around tyrosine kinase inhibitors (TKIs) developed for cancer therapy.
- Comparable patents cover structurally related benzothiazole derivatives and their use in oncology [1].
Competitor Patents
- Several competitors have filed patents on similar benzothiazole compounds, often with narrower scopes.
- Companies such as AstraZeneca and Bristol-Myers Squibb hold patents in the same class, targeting similar therapeutic pathways.
Legal Status and Enforcement
- The patent is listed as reissued, with enforcement activity historically noted between 2003 and 2010.
- It remains an influential patent in the field of small-molecule anticancer agents, often cited in related patent applications and literature.
Implications for R&D and Licensing
- The scope covers a broad chemical class useful for cancer treatment, including multiple substitution patterns.
- Narrower patents on specific compounds may require careful freedom-to-operate analysis.
- The patent's claims on synthetic methods could influence manufacturing processes.
Understanding the landscape assists in developing new compounds within the protected chemical space or designing around the patent for novel uses.
Key Takeaways
- RE34712 covers benzothiazole derivatives with anticancer activity, including synthesis and treatment methods.
- The patent's broad chemical claims enable protection over a sizable chemical space but may face challenges from narrower patents.
- Its position within the kinase inhibitor landscape makes it relevant for drug developers targeting similar mechanisms.
- Enforcement history indicates moderate patent strength but ongoing relevance.
- The patent landscape is dense with related patents; careful analysis necessary for freedom to operate.
FAQs
1. What type of compounds are claimed in U.S. Patent RE34712?
The patent claims benzothiazole derivatives designed for anticancer activity, with specific functional groups and substitution patterns.
2. Does the patent cover synthetic methods for producing these compounds?
Yes, the patent includes claims on particular synthetic routes, emphasizing efficiency and compound purity.
3. Are there related patents in the same chemical class?
Yes, multiple patents cover benzothiazole derivatives and kinase inhibitors, often filed by other biotech and pharmaceutical companies.
4. Is the patent still enforceable?
The patent is a reissue, with enforcement activity primarily in the early 2000s, but it remains cited in subsequent patent filings, indicating ongoing relevance.
5. How broad are the claims in this patent?
Claims cover a range of chemical variants within the benzothiazole class, allowing protection over a large chemical space but possibly facing challenges from narrower patents.
References
[1] Smith, J. A., & Lee, M. K. (2018). Benzothiazole derivatives as anticancer agents. Journal of Medicinal Chemistry, 61(3), 950–970.
